Can Immunotherapy Cure Stage 4 Melanoma?

Immunotherapy has turned stage 4 melanoma from a nearly uniformly fatal diagnosis into one where roughly a third to half of patients are alive five years later, and a meaningful subset appear to be functionally cured. The word “cure” still makes oncologists uneasy because late relapses can occur years after treatment ends, but the 10-year data from the largest checkpoint inhibitor trials now show survival curves that have essentially flattened, meaning most patients still alive at the three-year mark stay alive. That is a dramatic shift from the chemotherapy era, when median survival hovered around six months.

How Survival Has Shifted

Before checkpoint immunotherapy, advanced melanoma carried a grim prognosis. Median survival for inoperable stage 4 disease was roughly six months, and long-term survivors were rare exceptions. The approval of ipilimumab in 2011, followed by the PD-1 inhibitors nivolumab and pembrolizumab a few years later, rewrote those numbers. A large real-world analysis of patients with advanced melanoma treated in the immunotherapy era found a median overall survival of about 25 months and a five-year survival rate of nearly 36%.¹ That is a sixfold improvement in median survival compared with the pre-immunotherapy period.

These are averages, though, and the averages mask a wide spread. Patients who achieve a complete response, meaning their scans show no detectable cancer, do dramatically better. In that same analysis, patients with a complete response had a three-year overall survival above 90% measured from the time of that response.¹ For patients with only a partial response, the picture is still better than the old baseline but less favorable, with three-year survival closer to 57%.

The 10-Year Data From Combination Therapy

The strongest long-term evidence comes from the CheckMate 067 trial, which randomly assigned patients with untreated advanced melanoma to one of three arms: nivolumab plus ipilimumab (a combination of a PD-1 and a CTLA-4 inhibitor), nivolumab alone, or ipilimumab alone. At five years of follow-up, overall survival was 52% in the combination group and 44% with nivolumab alone, compared with 26% for ipilimumab alone.²

The trial recently reported 10-year outcomes. Median overall survival was about 72 months with the combination, compared with 37 months for nivolumab alone and 20 months for ipilimumab alone. Among patients in any treatment group who were progression-free at the three-year mark, melanoma-specific survival at 10 years ranged from 88% to 97%.³ That plateau is the closest thing to a cure signal that oncology data can offer. If your cancer has not progressed in three years on immunotherapy, your odds of dying from melanoma over the following seven years are very low.

What “Cure” Actually Means Here

Oncologists are careful about the word cure because they define it differently than most people do. In common usage, cured means the disease is gone forever. In oncology, a functional or statistical cure means that a group of patients has reached the point where their risk of dying from the cancer matches the background risk of death in the general population. The flattening survival curves from CheckMate 067 suggest many long-term responders have reached that point.

A French study of stage 4 melanoma patients who achieved a complete response on anti-PD-1 therapy and then stopped treatment found that five-year progression-free survival after achieving complete response was 79%, and five-year overall survival was 83%.⁴ Most of those patients remained disease-free years after finishing their treatment. A review of long-term immunotherapy outcomes noted that durable responses with more than six years of follow-up can persist after discontinuation, and while the hope of cure seems reasonable for many of these patients, late relapses do occur and no reliable biomarker currently predicts who will relapse.⁵

A systematic review and meta-analysis of patients who stopped immunotherapy found that the three-year progression-free survival rate after cessation was about 71%, and the three-year overall survival rate was about 86%.⁶ So even after patients stop their infusions, a large majority remain in remission. The absence of a clear relapse-prediction marker is what keeps oncologists from declaring anyone definitively cured.

How Checkpoint Immunotherapy Works

Your immune system has built-in brakes that prevent T cells from attacking your own tissues indefinitely. Cancers exploit those brakes. Two of the most important molecular brakes are CTLA-4, which dials down T-cell activity early in the immune response, mostly in lymph nodes, and PD-1, which suppresses T cells later, in the tissues where cancer lives.⁷ Melanoma cells commonly display PD-L1, the molecule that activates the PD-1 brake, causing T cells that recognize the tumor to become exhausted and stop killing.⁸

Drugs like nivolumab and pembrolizumab block PD-1, lifting that brake so exhausted T cells can reactivate and attack the tumor again.⁹ Ipilimumab blocks CTLA-4, releasing the earlier brake and broadening the pool of T cells that enter the fight. Combining both drugs hits the immune system’s suppression at two different stages, which explains the superior response rates of combination therapy and also its higher rate of side effects.

Why Some Patients Don’t Respond

Despite the optimistic long-term numbers, roughly half of patients with advanced melanoma either don’t respond to immunotherapy or respond initially and then relapse. The reasons fall into two broad buckets: inherent resistance, where the tumor was never vulnerable, and acquired resistance, where the tumor escapes after initially shrinking.

On the acquired side, researchers have identified specific genetic mutations in tumors that allow cancer cells to dodge the renewed immune attack. Mutations in JAK1 and JAK2, genes that help cells respond to immune signaling molecules like interferon gamma, allow cancer cells to ignore the alarm signals that T cells send. Another mutation, in a gene called B2M, prevents cancer cells from displaying their identity on their surface, essentially making them invisible to T cells.¹⁰ These mutations have been confirmed in multiple studies and represent a consistent theme in tumors that escape immunotherapy.¹¹

The tumor’s local environment also matters. Certain immune-suppressive cells, including regulatory T cells and a type of reprogrammed immune cell called tumor-associated macrophages, can create a protective shield around the cancer that blocks T cells from getting in even when checkpoint inhibitors have activated them.¹² This kind of resistance is especially relevant in sites like bone, where the local immune environment is naturally more suppressive.

What Predicts a Good Response

Researchers have been searching for reliable biomarkers to predict who will benefit most from immunotherapy. The total number of mutations in a tumor, known as tumor mutational burden, has been one candidate: more mutations generally mean more abnormal proteins that the immune system can recognize as foreign. But newer research suggests that the number of neoantigens, the specific altered proteins those mutations produce, predicts outcomes better than the raw mutation count.¹³ A prospective study found that neoantigen load had stronger predictive value for progression-free survival in melanoma patients than mutational burden alone, and that neoantigens capable of binding to a particular class of immune recognition molecules were especially useful for prediction.¹⁴

One of the more surprising findings in this area involves gut bacteria. An early study comparing the gut microbiomes of melanoma patients who responded to anti-PD-1 therapy and those who didn’t found that responders had higher microbial diversity and a greater abundance of specific bacterial families.¹⁵ This line of research is still developing, but it has fueled clinical trials of fecal transplants and probiotic strategies aimed at improving immunotherapy responses.

Brain Metastases

Melanoma has a notorious tendency to spread to the brain, and historically brain metastases meant a very poor prognosis because many drugs cannot cross the blood-brain barrier effectively. Immunotherapy has changed this picture, though outcomes remain worse than for patients without brain involvement. A study of patients with active brain metastases treated with pembrolizumab found that about a quarter had a brain-specific response, and 48% were alive at two years.¹⁶ Combination immunotherapy appears to produce the best outcomes for brain metastases, with a median overall survival of nearly 27 months for patients receiving dual checkpoint blockade as first-line treatment, compared with about 14 months for anti-PD-1 alone.¹⁷

Not All Melanomas Are Equal

Most of the impressive survival statistics come from cutaneous melanoma, the kind that arises on sun-exposed skin. Melanoma can also originate in mucous membranes (mucosal melanoma), on the palms, soles, or under nails (acral melanoma), or in the eye (uveal melanoma). These subtypes respond to immunotherapy far less well. After treatment with checkpoint inhibitors, patients with cutaneous melanoma had a median survival of about 45 months with roughly 46% alive at five years. By comparison, acral melanoma patients had a median survival of 17 months, mucosal melanoma patients about 18 months, and uveal melanoma patients just 12 months.¹⁸

Uveal melanoma is especially resistant. One study found no objective tumor responses among uveal melanoma patients treated with immunotherapy, compared with a modest response rate of about 12% in mucosal melanoma patients.¹⁹ These subtypes tend to have far fewer mutations than sun-driven cutaneous melanomas, which means fewer targets for the immune system to recognize. For patients with these rarer forms, the optimism around immunotherapy needs to be tempered considerably.

Newer Approaches Beyond Standard Checkpoints

For patients who don’t respond to PD-1 and CTLA-4 blockade, several newer strategies are in use or in advanced testing. One is the addition of a third immune checkpoint target called LAG-3. A combination of relatlimab, an anti-LAG-3 antibody, with nivolumab roughly doubled median progression-free survival compared with nivolumab alone, reaching about 10 months versus 4.6 months.²⁰ This combination was approved for first-line treatment of advanced melanoma and offers a different mechanism of action by targeting the exhaustion pathway from yet another angle.

Another promising approach is TIL therapy, which involves extracting immune cells directly from a patient’s tumor, expanding them into billions of copies in a lab, and infusing them back. Lifileucel, the first FDA-approved TIL therapy, was tested in patients whose disease had already progressed through checkpoint inhibitors. At five years of follow-up, about 31% of patients had an objective response, and almost a third of those responders were still responding at the five-year mark. Some patients who initially had partial responses later converted to complete responses more than a year after treatment.²¹ This is particularly meaningful because it works in patients for whom standard immunotherapy has already failed.

Personalized mRNA cancer vaccines, built on the same platform used for COVID-19 vaccines, are also in clinical trials for melanoma. These vaccines are designed to teach the immune system to recognize the unique set of mutations in an individual patient’s tumor. Early-phase results have generated enough interest that large trials combining mRNA vaccines with checkpoint inhibitors are underway.

Side Effects and What They Might Signal

Checkpoint inhibitors work by unleashing the immune system, and that unleashing is not always perfectly targeted. Immune-related side effects can affect almost any organ: the skin (rashes, vitiligo), the gut (colitis), the liver (hepatitis), the thyroid, the pituitary gland, the lungs, and more. In a study of melanoma patients on anti-PD-1 therapy, about 59% experienced some form of immune-related side effect.²²

There’s an intriguing and somewhat paradoxical relationship between side effects and outcomes. Patients who develop immune-related side effects tend to have better progression-free and overall survival than those who don’t, likely because both the anti-tumor response and the autoimmune side effects reflect a more active immune system.²² Vitiligo, a loss of skin pigment caused by the immune system attacking melanocytes, carries an especially strong association with good outcomes. However, the picture gets complicated for severe (grade 3-4) side effects, which were linked to higher response rates but worse overall survival in a meta-analysis, likely because severe toxicity sometimes forces patients to stop treatment.²³ Some side effects, particularly thyroid dysfunction and certain endocrine problems, can become permanent and require lifelong medication even after immunotherapy has ended.

Who Gets Access and Who Falls Through the Cracks

The survival gains from immunotherapy are real, but they are not distributed evenly. A recent analysis of stage 3 and 4 melanoma in the immunotherapy era found that five-year overall survival was 68% for privately insured patients but ranged from 43% to 52% for those on Medicare or uninsured. Patients treated at academic medical centers did better than those at community centers. Survival was 72% in patients under 50 but dropped to 33% in patients 75 and older. People in the lowest income and education groups also fared worse.²⁴ Some of this gap reflects biology: older patients have less robust immune systems. But insurance status and treatment setting are not biology. They reflect who can access specialized immunotherapy centers and afford the multi-year treatment courses these drugs require.

Living After Treatment

For the growing population of long-term survivors, life after immunotherapy is not a simple return to normal. A study examining quality of life in long-surviving advanced melanoma patients who had been treated with checkpoint inhibitors found that fatigue was the most commonly reported symptom, but overall symptom burden was moderate and quality of life was generally good.²⁵ That is reassuring, but fatigue should not be underestimated. It can persist for years and affect work, relationships, and daily function. Patients who developed endocrine side effects during treatment, particularly hypothyroidism or adrenal insufficiency, often need hormone replacement indefinitely. The psychological burden of living with the possibility of late relapse, even when the statistical odds favor continued remission, is another dimension that survival curves cannot capture.

Surveillance protocols after stopping immunotherapy remain an area of active debate. Most oncologists continue regular imaging for several years, but there is no consensus on how long monitoring should continue or when it is safe to consider someone truly out of the woods. The absence of a reliable blood test or biomarker to predict late relapse is the key gap. Until one exists, long-term survivors live in a space between cured and not yet confirmed cured, a distinction that matters deeply to the people in it even if the statistics are increasingly in their favor.

1
JAMA Network Open. Long-Term Survival in Patients With Advanced Melanoma
2
PubMed. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
3
PubMed Central. 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
4
PubMed Central. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
5
PubMed. Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma
6
PubMed Central. Survival after cessation of immunotherapies in melanoma: A systematic review and meta‐analysis
7
PubMed Central. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
8
PubMed Central. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway
9
Cell Reports. Tumor-infiltrating exhausted CD8+ T cells are tumor-specific and expanded by PD-1 blockade
10
PubMed Central. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
11
PubMed Central. Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma
12
PubMed Central. Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis
13
PubMed Central. Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
14
npj precision oncology. Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma
15
PubMed Central. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
16
PubMed Central. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
17
PubMed Central. Treating brain metastases in melanoma: What is the optimal CNS-directed and systemic management?
18
PubMed Central. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
19
PubMed Central. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
20
PubMed Central. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
21
PubMed Central. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
22
PubMed Central. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
23
PubMed. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
24
PubMed. Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era: Persistent Racial and Socioeconomic Disparities
25
PubMed Central. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors